TLSI

TriSalus Life Sciences, Inc. Common Stock

4.76

USD

TLSI Earnings Reports

Positive Surprise Ratio

TLSI beat 3 of 8 last estimates.

38%

Next Report

Date of Next Report

Mar 24, 2026

Estimate for Q4 25 (Revenue/ EPS)

$13.17M

-$0.13

Implied change from Q3 25 (Revenue/ EPS)

+13.86%

-48.00%

Implied change from Q4 24 (Revenue/ EPS)

+59.42%

-67.50%

TriSalus Life Sciences, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, TLSI reported earnings of -0.25 USD per share (EPS) for Q3 25, missing the estimate of -0.15 USD, resulting in a -65.02% surprise. Revenue reached 11.57 million, compared to an expected 11.99 million, with a -3.58% difference. The market reacted with a +3.87% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 13.17 million USD, implying an decrease of -48.00% EPS, and increase of 13.86% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Phibro Animal Health Corporation Class A

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.68

Actual

$0.87

Surprise

+27.30%

Canopy Growth Corporation Common Shares

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.04

Actual

-$0.13

Surprise

-198.00%

Aurora Cannabis Inc. Common Shares

Report Date

Feb 04, 2026 For Q3 26

Estimate

$0.21

Actual

$0.12

Surprise

-42.72%

High Tide Inc. Common Shares

Report Date

Jan 29, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.56

Surprise

0.00%

Stryker Corporation

Report Date

Jan 29, 2026 For Q4 25

Estimate

$4.43

Actual

$4.47

Surprise

+0.69%

Boston Scientific Corp.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.78

Actual

$0.80

Surprise

+1.61%

ResMed Inc.

Report Date

Jan 29, 2026 For Q2 26

Estimate

$2.75

Actual

$2.81

Surprise

+2.15%

GE HealthCare Technologies Inc. Common Stock

Report Date

Feb 04, 2026 For Q4 25

Estimate

$1.42

Actual

$1.44

Surprise

+0.96%

Envista Holdings Corporation Common stock, $0.01 par value per share

Report Date

Feb 05, 2026 For Q4 25

Estimate

$0.32

Actual

$0.38

Surprise

+15.43%

Prestige Consumer Healthcare Inc.

Report Date

Feb 05, 2026 For Q3 26

Estimate

$1.15

Actual

$1.13

Surprise

-1.36%

FAQ

What were TriSalus Life Sciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, TriSalus Life Sciences, Inc. Common Stock reported EPS of -$0.25, missing estimates by -65.02%, and revenue of $11.57M, -3.58% below expectations.

How did the market react to TriSalus Life Sciences, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 3.87%, changed from $4.39 before the earnings release to $4.56 the day after.

When is TriSalus Life Sciences, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 24, 2026.

What are the forecasts for TriSalus Life Sciences, Inc. Common Stock's next earnings report?

Based on 9 analysts, TriSalus Life Sciences, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $13.17M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.